Study on KB-0742 for Patients with Relapsed or Hard-to-Treat Solid Tumors or Non-Hodgkin Lymphoma
Sponsor: Kronos Bio
Sponsor score: 0
Inactive
ClinicalTrials ID:NCT04718675
This clinical trial is testing the safety and tolerability of a new drug, KB-0742, in patients with solid tumors or Non-Hodgkin Lymphoma that have not responded to previous treatments or have returned after treatment.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The study is divided into two parts. Part 1 focuses on finding a safe dose of KB-0742 for patients with relapsed or refractory solid tumors or Non-Hodgkin Lymphoma. Part 2 aims to further evaluate the safety of KB-0742 in specific groups of patients.
Eligibility Criteria
Inclusion Criteria
- Adults aged 18 and older, or teens aged 12 and older weighing at least 40 kg, with certain types of tumors.
- Willing to provide consent to participate.
- Part 1: Patients with any relapsed or refractory solid tumor or specific types of tumors like small cell lung cancer, ovarian cancer, or certain lymphomas.
- Part 2: Patients with confirmed solid tumors who have no other treatment options.
- Must provide a tumor sample for testing.
- Good overall health with a performance status of 0 or 1.
- Must have measurable disease.
- Adequate bone marrow and organ function.
- Must have recovered from previous treatment side effects.
- Agree to use effective birth control during the study and for 3 months after.
Exclusion Criteria
- Recent use of other cancer treatments within 4 weeks.
- Recent surgery or radiation therapy.
- History of organ transplant within 6 months.
- Active cancer in the brain or spinal cord unless stable for 3 months.
- Recent stroke or brain bleeding.
- History of seizures or taking seizure medications.
- Active infections needing treatment.
- Active COVID-19 infection.
- Significant heart disease or uncontrolled high blood pressure.
- Prolonged QT interval on an ECG.
- Active HIV, hepatitis B, or hepatitis C infection.
- Other uncontrolled medical conditions.
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.
